Donanemab Slows Clinical Progression in Early Alzheimer Disease

MONDAY, July 17, 2023 -- Donanemab slows clinical progression among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, according to a study published online July 17 in the Journal of the American Medical Association...